Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic ...

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

Left ventricular noncompaction is characterized by deep trabeculations in the LV endocardium in association with left ventricular hypertrophy, dilation or hypertrophy/dilation. Noncompaction of the ...

Demographic, systemic sclerosis (SSc)-specific, and cardiac factors raised the risk for left ventricular systolic dysfunction (LVSD) in a study of patients with SSc. Researchers used the Johns Hopkins ...

Cardiotoxicity is a well-established complication of multiple cancer therapeutics, and the one of the most prominent effects that limits the use of these agents is in the form of left ventricular ...

Please provide your email address to receive an email when new articles are posted on . HF and LV dysfunction affect about 9% of adults aged 60 years and older, and there are effective treatments to ...

Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe left ventricular dysfunction and extensive coronary artery disease ...